Regulations for Good Clinical Practice Article 106
The investigator shall immediately report any serious adverse events to the sponsor, and shall provide detailed, written reports as soon as possible. The investigator shall immediately report any suspected unexpected serious adverse drug reactions to the Ethics Committee. However, those SAEs that the protocol or other document identifies as not needing immediate reporting shall not apply.The sponsor shall report any suspected unexpected serious adverse reactions that are fatal or life-threatening to the Competent Authority or the contracted organization within 7 days after being aware of the event, and shall provide detailed written documents within 15 days after being aware of the event.The sponsor shall report all the other suspected unexpected serious adverse reactions to the Competent Authority or the contracted organization and provide detailed written documents within 15 days after being aware of the event.The subjects’ identity should be coded in the oral and written reports mentioned in paragraph 1 that should not reveal subjects’ names, ID numbers, addresses, or any other information which may reveal subject’s personal identity.The serious adverse events and serious adverse drug reactions are defined and announced by the Competent Authority.
中文原文 藥品優良臨床試驗作業準則第106條
受試者發生任何嚴重不良事件,試驗主持人應立即通知試驗委託者,並儘快提供詳細書面報告。
發生未預期之嚴重藥品不良反應,試驗主持人應立即通知人體試驗委員會。
但若試驗計畫書或其他文件明確排除者,不在此限。
試驗委託者獲知未預期之死亡或危及生命之嚴重藥品不良反應,應於獲知日起七日內通報主管機關或其委託機構,並在獲知日起十五日內提供詳細書面資料。
試驗委託者獲知未預期之死亡或危及生命以外之嚴重藥品不良反應,應於獲知日起十五日內通報主管機關或其委託機構,並提供詳細書面資料。
第一項之口頭及書面報告,應以受試者代碼代表受試者之身分,不得顯示受試者之姓名、身分證統一編號、住址或其他可辨認受試者身分之資訊。
嚴重不良事件與嚴重藥品不良反應之項目由主管機關公告之。
發生未預期之嚴重藥品不良反應,試驗主持人應立即通知人體試驗委員會。
但若試驗計畫書或其他文件明確排除者,不在此限。
試驗委託者獲知未預期之死亡或危及生命之嚴重藥品不良反應,應於獲知日起七日內通報主管機關或其委託機構,並在獲知日起十五日內提供詳細書面資料。
試驗委託者獲知未預期之死亡或危及生命以外之嚴重藥品不良反應,應於獲知日起十五日內通報主管機關或其委託機構,並提供詳細書面資料。
第一項之口頭及書面報告,應以受試者代碼代表受試者之身分,不得顯示受試者之姓名、身分證統一編號、住址或其他可辨認受試者身分之資訊。
嚴重不良事件與嚴重藥品不良反應之項目由主管機關公告之。